Clinical pharmacology of deferasirox

Clinical Pharmacokinetics

Volumn 53, Issue 8, 2014, Pages 679-694

  Tanaka, Chiaki ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; IRON; BENZOIC ACID DERIVATIVE; IRON CHELATING AGENT; PROTEIN BINDING; TRIAZOLE DERIVATIVE;

CLINICAL PHARMACOLOGY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; HEMODIALYSIS; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON INTAKE; PHARMACODYNAMICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; ABSORPTION; BIOAVAILABILITY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG INTERACTION; METABOLIC CLEARANCE RATE; TISSUE DISTRIBUTION;

ABSORPTION, PHYSICOCHEMICAL; BENZOATES; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; HUMANS; IRON CHELATING AGENTS; METABOLIC CLEARANCE RATE; MOLECULAR STRUCTURE; PROTEIN BINDING; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 84905560553     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0151-4     Document Type: Review

References (80)

1. Anderson GJ. Mechanisms of iron loading and toxicity. Am J Hematol. 2007;82:1128-31.
2. Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721-41.
3. Thalassaemia International Federation. Guidelines for the clinical management of thalassaemia, 2nd revised edition; 2008. http://www.thalassaemia. org.cy/wp-content/uploads/pdf/educational-programmes/Publications/ Guidelines%20%282008%29/Thalassaemia%20Guidelines%20ENGLISH.pdf. Accessed 6 Jun 2014.
4. Smith-Whitley K, Thompson AA. Indications and complications of transfusions in sickle cell disease. Pediatr Blood Cancer. 2012;59:358-64.
5. Kurtin SE. Myelodysplastic syndromes: diagnosis, treatment planning, and clinical management. Oncology (Williston Park). 2007;21:41-8.
6. Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in β-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood. 2007;109:5027-35.
7. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with β-thalassemia intermedia. Haematologica. 2011;96:1605-12.
8. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115:1886-92.
9. ® (deferasirox) US prescribing information; 2013. http://www.pharma.us.novartis.com/product/pi/pdf/ exjade.pdf. Accessed 6 Jun 2014.
10. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood. 2006;107:3455-62.
11. Cappellini MD, Porter JB, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. 2010;95:557-66.
12. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118:884-93.
13. ®, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873-80.
14. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168-76.
15. Taher AT, Porter J, Viprakasit V, et al. Deferasirox significantly reduces iron overload in non-transfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120:970-7.
16. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92:1485-93.
17. ®, ICL670), a once-daily oral iron chelator, in patients with sickle cell disease (SCD). Blood. 2007;110(11):abst 3395.
18. Pennell D, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2 in patients with beta-thalassemia major. Haematologica. 2012;97:842-8.
19. Pennell DJ, Porter JB, Piga A, et al. A 1-year randomized controlled trial of deferasirox versus deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA). Blood. 2014;123:1447-54.
20. Daar S, Pathare A, Nick H, et al. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia. Eur J Haematol. 2009;82:454-7.
21. al Refaie FN, Sheppard LN, Nortey P, et al. Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload. Br J Haematol. 1995;89:403-8.
22. Cabantchik ZI, Breuer W, Zanninelli G, et al. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol. 2005;18:277-87.
23. Porter JB. Deferoxamine pharmacokinetics. Semin Hematol. 2001;38(Suppl 1):63-8.
24. Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9:2391-402.
25. McLeod C, Fleeman N, Kirkham J, et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technol Assess. 2009;13:iii-iv, ix-xi, 1-121.
26. Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003;10:1065-76.
27. Deferasirox. In: O'Neil MJ, editor. The Merck Index - an encyclopedia of chemicals, drugs, and biologicals. Whitehouse Station: Merck and Co., Inc.; 2006. p. 483.
28. Nick H, Wong A, Acklin P, et al. ICL670A: preclinical profile. Adv Exp Med Biol. 2002;509:185-203.
29. Sechaud R, Dutreix C, Balez S, et al. Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks. Int J Clin Pharmacol Ther. 2008;46:102-8.
30. Novartis Pharmaceuticals UK Ltd. Summary of product characteristics - EXJADE 125 mg, 250 mg, 500 mg dispersible tablets; 2013. http://www.medicines. org.uk/emc/medicine/18805/SPC/. Accessed 6 Jun 2014.
31. Heinz U, Hegetschweiler K, Acklin P, et al. 4-[3,5-Bis(2-hydroxyphenyl)- 1,2,4-triazol-1-yl]-benzoic acid: a novel, efficient and selective iron(iii) complexing agent. Angew Chem Int Ed Engl. 1999;38:2568-70.
32. Rouan MC, Marfil F, Mangoni P, et al. Determination of a new oral iron chelator, ICL670, and its iron complex in plasma by high-performance liquid chromatography and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 2001;755:203-13.
33. Skerjanec A, Wang J, Maren K, et al. Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol. 2010;50:205-13.
34. Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597-602.
35. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci. 1998;850:191-201.
36. 2, for rat, marmoset, rabbit, mouse, dog, and human. Drug Metab Dispos. 2006;34:971-5.
37. Sechaud R, Robeva A, Belleli R, et al. Absolute oral bioavailability and disposition of deferasirox in healthy human subjects. J Clin Pharmacol. 2008;48:919-25.
38. Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol. 2003;43:565-72.
39. Galanello R, Piga A, Cappellini MD, et al. Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol. 2008;48:428-35.
40. Goldberg SL, Giardina PJ, Chirnomas D, et al. The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013;60:1507-12.
41. Bruin GJ, Faller T, Wiegand H, et al. Pharmacokinetics, distribution, metabolism and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos. 2008;36:2523-38.
42. Waldmeier F, Bruin GJ, Glaenzel U, et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos. 2010;38:808-16.
43. Ginsberg G, Hattis D, Sonawane B, et al. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 2002;66:185-200.
44. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84:417-23.
45. Sechaud R, Dumortier T, Balez S. Deferasirox does not induce QT/QTc-prolongation in healthy subjects. Int J Clin Pharmacol Ther. 2009;47:321-7.
46. ®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan. Int J Hematol. 2008;88:73-81.
47. Galanello R, Piga A, Forni GL, et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica. 2006;91:1343-51.
48. Vichinsky E, El-Beshlawy A, Alzoebie A, et al. Interim safety and effectiveness results from a 5-year observational study of deferasirox in pediatric patients aged 2-<6 years at enrollment [abstract]. Blood. 2012;120(21):abst 2125.
49. Taher AT, Musallam KM, Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin. 2009;33(Suppl 1):S46-57.
50. Mallat ME, Sharara AI. Treatment and prevention of hepatitis B and C in thalassemia. Hemoglobin. 2009;33(Suppl 1):S139-44.
51. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant. 2014;29:255-9.
52. Maker GL, Siva B, Batty KT, et al. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. Nephrology (Carlton). 2013;18:188-93.
53. Sechaud R, Robeva A, Belleli R, et al. Absence of an effect of a single-dose deferasirox on the steady-state pharmacokinetics of digoxin. Int J Clin Pharmacol Ther. 2008;46:519-26.
54. Rolan PE. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmacol. 1994;37:125-8.
55. Sansom LN, Evans AM. What is the true clinical significance of plasma protein binding displacement interactions? Drug Saf. 1995;12:227-33.
56. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115-21.
57. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997;73:67-74.
58. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377:1663-72.
59. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med. 1995;332:1317-22.
60. Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol. 1998;20:26-31.
61. Voskaridou E, Bilalis A, Christoulas D, et al. Prolonged administration of hydroxyurea reduces morbidity and mortality in adult patients with sickle-cell syndromes: final analysis of a 17-year, single center, trial [abstract no. 1079]. Haematologica. 2009;94(Suppl 2):435.
62. Vichinsky E, Torres M, Minniti CP, et al. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Am J Hematol. 2013;88:1068-73.
63. Sweiss K, Patel P, Rondelli D. Deferasirox increases BU blood concentrations. Bone Marrow Transplant. 2012;47:315-6.
64. Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004;363:357-62.
65. Hernando D, Levin YS, Sirlin CB, et al. Quantification of liver iron with MRI: state of the art and remaining challenges. J Magn Reson Imaging. Epub 2014 Mar 3.
66. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology Am Soc Hematol Educ Program. 2009;215-21.
67. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-61.
68. Taher A, Elalfy MS, Al Zir K, et al. Importance of optimal dosing >30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haematol. 2011;87:355-65.
69. Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood. 2009;114:4009-13.
70. Chang HH, Lu MY, Liao YM, et al. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent beta-thalassemia. Pediatr Blood Cancer. 2011;56:420-4.
71. Pongtanakul B, Viprakasit V. Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose. Blood Cells Mol Dis. 2013;51:96-7.
72. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331:567-73.
73. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 1996;95:26-36.
74. Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet. 2000;355:2051-2.
75. Porter JB, Evangeli M, El-Beshlawy A. The challenges of adherence and persistence with iron chelation therapy. Int J Hematol. 2011;94:453-60.
76. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. 2009;147:752-9.
77. Vichinsky E, Onyekwere O, Porter J, et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501-8.
78. ®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol. 2011;154:387-97.
79. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia. Blood. 2010;115:2364-71.
80. Piga A, Fracchia S, Lai ME, et al. Two-year renal hemodynamic effects of deferasirox in patients with transfusion-dependent β-thalassemia [abstract no. 3257]. Blood. 2012;120(21):3257.